Series — KOSDAQ Structural 2026 (Part 4 of 4, bonus) ① Capital Inflow Triggers & VC Ranking — the policy setup ② IPO Class of 2023-2026: Where the Tenbaggers Live — the post-IPO winners ③ KR Tenbaggers Full 10× Census — the realized 3-year winners ④ This post — where sell-side isn’t yet, and why that matters

The Premise

If tenbaggers cluster, so does sell-side attention. And the gap between where analysts publish and where the structural winners sit is where variant perception lives.

We pulled every broker report filed to Hankyung Consensus (한경컨센서스) over the trailing 3 months — Jan 23 to Apr 23, 2026 — across 11 brokers that feed the platform (LS, Eugene, SK, iM, Meritz, Yuanta, Hanwha, IBK, Daishin, Sangsangin, KoreaIR). Only 52 KOSDAQ names got ≥2 broker coverage in that window.

That’s out of ~1,777 KOSDAQ stocks.

Data Caveat (Say It Once, Loud)

Hankyung does not include Samsung, Mirae Asset, Kiwoom, NH, Hana, Shinhan, KB, Korea Investment, DB, or Daol — 10+ major houses. So “2 brokers on Hankyung” typically maps to 4-6 actual brokers in the real market. That matters for a few names below where the published count understates the truth.

• [Fact] 52 names passed the 2-broker / 3-month threshold on Hankyung
• [Inference] True market-wide coverage is ~1.8-2.5× the reported number
• [Blocked] Target-price consensus and recommendation distributions are not computable from this dataset (needs FnGuide)

The Sector Map — 52 Names, 8 Buckets

Market-cap distribution:

• L (>1T KRW): 27 names (52%)
• M (300B-1T): 16 (31%)
• S (100-300B): 8 (15%)
• XS (<100B): 1 (2%)

The structurally interesting bucket is the 9 small-caps ≤300B KRW with ≥2 brokers. That combination — small enough to be inefficient, covered enough to have a publishable thesis — is where variant perception can actually be framed.

The 9 Small-Caps

One structural read-through: 5 of 9 have KoreaIR Council as one of the two “brokers.” KoreaIR publishes sponsored/initiation research — quality varies, but it’s not an independent second opinion. Subtract that, and the real publishable-thesis count drops to 1 broker + initiation note for many of these. That’s thinner than the raw coverage implies — and thinner coverage is where variant perception is cheapest.

Six Thesis Archetypes

A — Defense Export, Tier-2 Beneficiary (2 names)

Coats Technologies printed 1,190B KRW order backlog at 2024Q3 with UAE / Saudi / Iraq entering volume production in 2026. [Fact] Cheongung-II hit 100% intercept rate on eight cruise missiles in a March 2026 UAE engagement (MBC, FT) — the kind of live-combat validation that historically re-rates defense export names globally.

The tier-1 names (Hyundai Rotem, LIG Nex1) are priced-in. Coats is the lock-in supplier one layer down the stack.

Victek’s “structurally growing EW niche” is softer — analyst defensive framing rather than a numbers-backed thesis. Needs quant validation.

B — AI / Datacenter Power Chain (1 name)

This is the strongest choke-point candidate in the entire set.

• Bloom-Oracle 2.8GW agreement (Apr 2026)
• Bloom-AEP $2.65B agreement (Jan 2026)
• Hanyang Securities: Amosense SOFC revenue 100B KRW in 2026 → 400B KRW in 2027 (4×)
• Bloom’s strategic China supply-chain diversification = direct Amosense tailwind
• Peers in the Bloom supply chain (Vinatech, Kosess) have already rallied; Amosense is still sitting at 160-220B KRW market cap

This is the classic NRE-to-volume J-curve: 2024-25 = pilot, 2026 = first volume (100B), 2027 = scale (400B). Same shape as the ADT / Gaonchips cycle a few years back. The consensus hasn’t reflected the 2027 step-up yet.

C — Value-Up / Activist (1 name)

Broke a 14-year range in January. IBK target price 46,000 KRW (+20% revision), LS 40,000. Already hit 52-week high at 31,500 and is digesting. Most of the first leg is priced in. The second catalyst — actual buyback cancellation or dividend expansion — is the checkpoint.

Warning: don’t generalize this into “value-up = automatic rerating.” It worked here because the activist forced a specific, disclosable action. Without that forcing function, a governance thesis is just vibes.

D — Biotech Pipeline Inflection (1 name)

Binary. L/O lands → re-rating. L/O falls through → drawdown. Typical small-cap biotech shape. Latest publishable research is Eugene’s Apr 13 NDR note; KoreaIR’s piece is from Feb 25. [Speculation] on the outcome.

E — Niche Tech Leadership (3 names)

These are the “quality small-cap” cluster. Raon’s “aspirations” framing tells you earnings are still lagging the story. Genians is a slow compounder — the edge is in the operating-leverage step-up if enterprise security capex cycle turns. Gaon is cycle-sensitive; NDR narrative (“strong demand”) needs P&L confirmation.

F — Dividend / Low-Growth (1 name)

94B KRW cap, decent dividend + improving margins, minimal growth. Not alpha — carry. Belongs in a yield sleeve, not a variant-perception book.

Variant Perception Ranking

Other Structural Observations

Entertainment coverage is anomalously deep. SM at 8 brokers / 14 reports and YG at 7 / 12 is mid-cap-index-level density. Within the same sector, SAMG Entertainment at 2 / 2 is the “quasi-coverage gap” candidate — covered enough to have a framework, sparse enough that a re-rating under a hit IP thesis has room to run.

Structural coverage deserts — consumer, chemicals, autos, transport, construction. 0-1 names each. Partly because KOSDAQ listings in those sectors are sparse to begin with, but for names like Silicon2 (3T KRW cap, single broker coverage), the absence of peer benchmarking is a real risk — analysts cannot triangulate without comparables.

Defense small-caps are getting real traffic. Three names in the 100-300B cap range, all with recent notes (Apr 7, Apr 15, Apr 17). Coats Technologies at 124B KRW with 3 brokers is coverage-density-per-cap that typically precedes promotion into the sell-side consensus proper.

KoreaIR-Council inflation. ~5 of the 9 small-caps have one of their two “covers” as KoreaIR Council. That is an initiation-style sponsored research product — useful, but not independent second-opinion coverage. Filtering it out, most of these names are really “1 broker + initiation note” — meaningfully thinner than the raw count suggests, and a better reflection of where the variant-perception opportunity actually lives.

Invalidation Triggers

Because small-cap theses die quietly, write the kill condition up front.

TL;DR

KOSDAQ sell-side coverage is concentrated in 52 names — just 3% of the index. Within that, 9 small-caps (≤300B KRW) cluster into 6 thesis archetypes: defense tier-2, AI power chain, activist value-up, biotech inflection, niche tech, and dividend carry.

Two names stand out on the choke-point / priced-in matrix:

• Amosense — Bloom Energy ceramic-substrate bottleneck, 4× revenue step-up not in consensus
• Coats Technologies — K2 SBC sole supplier + Cheongung-II live-combat validation

Daeyang Electric already ran on the value-up story — most of the first-leg move is priced in; the second catalyst is the decision point. The rest sit in weaker variant-perception positions: Tiumbio is binary, Raon is a beta trade, Sangsang JLS is carry.

If sell-side hasn’t written it down, it isn’t priced. These 9 names are the cheapest option we found on that asymmetry.

This bonus post closes the KOSDAQ Structural 2026 series. Part 1: VC ranking. Part 2: IPO tenbagger class. Part 3: Full 10× census.

Nothing here is investment advice. All names covered are idea-generation candidates for further diligence.